

MedInvent, LCC announces first clinical data published on the NasoNeb Nasal Nebulizer

White Bear Lake, MN. MedInvent, LLC announced today the publication of the study “*Prospective evaluation of aerosol delivery by a powered nasal nebulizer in the cadaver model*” *International Forum of Allergy & Rhinology* R. Peter Manes Liyue Tong Pete S. Batra. This first peer-reviewed paper demonstrates the deposition of the NasoNeb Nasal Nebulizer in the intranasal and paranasal sinus cavity. The NasoNeb Nasal Nebulizer consistently deposited medication throughout the nose and sinuses across 3 different sinus surgery states.

“We believe the results seen in this study correlate well with the clinical reports we are hearing from otolaryngologist and allergists treating patients with the NasoNeb Nasal Nebulizer. Designed specifically for intranasal and paranasal sinus delivery, there is no other device with the delivery characteristics of the patented NasoNeb Nasal Nebulizer on the market today. The unique combination of plume shape, airflow and particle size enables the NasoNeb Nasal Nebulizer to perform the way it did in the study. Further studies to investigate the clinical impact of topical therapy delivered via the NasoNeb Nasal Nebulizer are planned with one already underway.” said William Flickinger, Managing Partner at MedInvent, LLC.

The study was supported by a grant from MedInvent, LLC, whose personnel also provided technical support to the investigators. The abstract and full-text are available on-line at <http://onlinelibrary.wiley.com/doi/10.1002/alr.20057/abstract>.

The NasoNeb Nasal Nebulizer is available by prescription through compounding pharmacies across the US.

For more information, please visit the MedInvent, LLC website at www.nasoneb.com.

About MedInvent, LLC

MedInvent, LLC is a privately-held limited liability corporation established in 2008 with operations in White Bear Lake, MN. MedInvent develops and markets the NasoNeb Family of drug delivery systems for the topical delivery of medication to the nasal and paranasal sinus cavities. The NasoNeb Nasal Nebulizer is indicated for topical drug delivery to the nasal cavity for drugs formulated for inhalation. With sales operations in the US, New Zealand and Taiwan, the NasoNeb Family of Products has been used by nearly 9,000 patients since 2009.

Contact William Flickinger at 651-236-8545 for more information or visit our website at www.nasoneb.com

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risk. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In

addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.